Drug Price Regulation: Recent Trends and Downstream Neglected Issues

  • Joan-Ramón Borrell
Part of the Economía de la Salud y Gestión Sanitaria book series (SESGS)


This paper surveys the literature on price regulation in the pharmaceutical sector. After summarizing the well-known results of the available literature, the paper focuses on identifying the remaining open questions, and proposing new research avenues on some neglected issues. It argues that downstream agents such as pharmacists have an important role to play to make price regulation and procurement mechanisms work efficiently, thus stimulating the launch of truly innovative new drugs.


Reference Price Drug Price Price Regulation Generic Entry Parallel Trading 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abood R. Pharmacy Practice and the Law. 5th ed. Sudbury (MA): Jones and Bartlett Publishers; 2007.Google Scholar
  2. Aronsson T, Bergman M, Rudholm N. The impact of generic drug competition on brand name market shares. Evidence from micro data. Review of Industrial Organization. 2001;19:425–435.CrossRefGoogle Scholar
  3. Arruñada B. Managing Competition in Professional Services and the Burden of Inertia. In: Ehlermann C-D, Atanasiu I, editors. European Competition Law Annual 2004: The Relationship between Competition Law and the (Liberal) Professions. Oxford and Portland, Oregon: Hart Publishing; 2006. p. 51–71.Google Scholar
  4. Bae JP. Drug patent expirations and the speed of generic entry. Health Services Research. 1997;32:187–201.Google Scholar
  5. Bergman M, Rudholm N. The relative importance of actual and potential competition: Empirical evidence from the pharmaceuticals market. J Industrial Economics. 2003;51:455–467.CrossRefGoogle Scholar
  6. Borrell JR. Pharmaceutical Price Regulation: A Study on the Impact of the Rate-of-Return Regulation in the UK. Pharmacoeconomics. 1999;15(3):291–303.PubMedCrossRefGoogle Scholar
  7. Borrell JR. Drug price differentials caused by formularies and price caps. Int J Economics Business. 2003;10:37–50.Google Scholar
  8. Borrell JR, Costas A, Nonell R. Regulation and competition in the market for pharmaceuticals. In: Puig-Junoy J, editor. The public financing of pharmaceuticals: An economic approach. Cheltenham and Northampton: Edward Elgar; 2005. p. 59–83.Google Scholar
  9. Borrell JR, Merino A. Los beneficios de una competencia incipiente: descuentos y bonificaciones a oficinas de farmacia. In: Cases L, editor. Anuario de la Competencia 2006. Madrid: Fundación ICOMarcial Pons; 2007.Google Scholar
  10. Borrell JR. Pricing and Patents of HIV/AIDS Drugs in Developing Countries. Applied Economics. 2007;39(4):505–518.CrossRefGoogle Scholar
  11. Borrell JR. Assessing Excess Profits from Different Entry Regulations. Working Paper Num. 2009-03. Xarxa de Referencia en Economia Aplicada, Barcelona.Google Scholar
  12. Brekke KR, Königbauer I, Straume OR. Reference pricing of pharmaceuticals. J Health Econ. 2007;26: 613–642.PubMedCrossRefGoogle Scholar
  13. Cabrales A, Jiménez-Martín S. The Determinants of Pricing in Pharmaceuticals: Are U.S. prices really higher than those of Canada? Mimeo 2007.Google Scholar
  14. Costa-Font J, Puig-Junoy J. The pharmaceutical market regulation in Spain: Is drug cost-containment under question? J Pharmaceuticals Finance, Economics and Policy. 2005;13:33–49.CrossRefGoogle Scholar
  15. COFV & FEFE. Marco Legal Comparado de la Farmacia en Europa. Colegio Oficial de Farmacéuticos de Valencia y Federación Empresarial de Farmacéuticos Españoles; 2007.Google Scholar
  16. Danzon PM, Chao WL. Does regulation drive out competition in pharmaceutical markets? J Law Econ. 2000;43:311–357.CrossRefGoogle Scholar
  17. Danzon PM, Chao WL. Cross-national price differences for pharmaceuticals: how large, and why? J Health Econ. 2000;19:159–195.PubMedCrossRefGoogle Scholar
  18. Danzon PM, Ketcham JD. Reference pricing of pharmaceuticals for Medicare: Evidence from Germany, the Netherlands and New Zealand. Forum for Health Economics & Policy, 7. 2004 (Frontiers in Health Policy Research), Article 2. Retrieved from Scholar
  19. Danzon PM, Wang YR, Wang L. The impact of price regulation on the launch delay of new drugs — evidence from twenty-five major markets in the 1990s. Health Economics. 2005;14:269–292.PubMedCrossRefGoogle Scholar
  20. Danzon PM, Furukawa M. Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets. NBER Working Paper Series; 2011.Google Scholar
  21. Daunfeldt SO, Rudholm N, Bergström F. Entry into Swedish retail and wholesale trade markets. Rev Industrial Organization. 2006;29:213–225.CrossRefGoogle Scholar
  22. Daunfeldt SO, Rudholm N. Revenues as a proxy for profits: A cautionary note. Applied Economic Letters. 2009;16:679–681.CrossRefGoogle Scholar
  23. de Pouvourville, G (2006). “Risk-sharing agreements for innovative drugs: a new solution to old problems?” Eur J Health Econ. 7(3):155–157.PubMedCrossRefGoogle Scholar
  24. Domínguez B, Ganuza JJ, Llobet G. R&D in the Pharmaceutical Industry: A World of Small Innovations. Manage Sci. 2008.55:539–551.Google Scholar
  25. Duggan M, Morton SF. The Effect of Medicare Part D on Pharmaceutical Prices and Utilization. Mimeo; 2008.Google Scholar
  26. Duggan M, Morton SF. “The Distortionary Effects of Government Procurement: Evidence for Medicaid Prescription Drug Purchasing. Quarterly Journal of Economics. 2006;1:30.Google Scholar
  27. Ekelund M. Generic entry before and after the introduction of reference prices. In: Ekelund M, editor. Competition and innovation in the Swedish pharmaceutical market. Dissertation. Chapter 4. Stockholm School of Economics; 2001. p. 1–17.Google Scholar
  28. Ekelund M, Persson B. Pharmaceutical pricing in a regulated market. Review of Economics and Statistics. 2003;85:298–306.CrossRefGoogle Scholar
  29. Ellison G, Ellison SF. Strategic Entry Deterrece and the Behaviour of Pharmaceutical Incumbents Prior to Patent Expiration. NBER Working Paper; 2007.Google Scholar
  30. European Commission. Pharmaceutical Sector Inquiry. Preliminary Report. DG Competition Staff Working Paper, Brussels; 2008.Google Scholar
  31. Evans R. Supplier-Induced Demand: Some Empirical Evidence and Implications. In: Perlman M, editor. The Economics of Health and Medical Care. London: Macmillan; 1974. p. 162–173.Google Scholar
  32. Frank RG, Salkever DS. Generic entry and the pricing of pharmaceuticals. J Economics Management Strategy. 1997;6:75–90.CrossRefGoogle Scholar
  33. Grabowski HG, Vernon JM. Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 drug act. J Law Econ. 1992;35:331–350.CrossRefGoogle Scholar
  34. Grossman G, Lai E. International Protection of Intellectual Property. Am Econ Rev. 2004;94:1635–1653.CrossRefGoogle Scholar
  35. Hollis A. How do brands ‘own generics’ affect pharmaceutical prices? Rev Industrial Organization. 2005;27:329–350.CrossRefGoogle Scholar
  36. Hong SH, Shepherd MD, Scoones D, Wan TTH. Product-line extensions and pricing strategies of brandname drugs facing patent expiration. J Managed Care Pharmacy. 2005;11:746–754.Google Scholar
  37. Hudson J. Generic take-up in the pharmaceutical market following patent expiry: A multi-country study. Int Rev Law Econ. 2000;24:103–112.Google Scholar
  38. Iizuka T. Generic entry in a regulated pharmaceutical market. Japanese Econ Rev. 2009;60:63–81.CrossRefGoogle Scholar
  39. Jansson E. Libre competencia frente a regulación en la distribución minorista de medicamentos. Rev Econ Apl. 1999;19:85–112.Google Scholar
  40. Königbauer I. Advertising and generic market entry. J Health Econ. 2006;26:286–305.PubMedCrossRefGoogle Scholar
  41. Kyle M. Pharmaceutical Price Controls and Entry Strategies. Rev Econ Statistics. 2007;89(1):88–99.CrossRefGoogle Scholar
  42. López-Casasnovas G, Puig-Junoy J. Review of the literature on reference pricing. Health Policy. 2000;54:87–123.PubMedCrossRefGoogle Scholar
  43. Magazzini L, Pammolli F, Riccaboni M. Dynamic competition in pharmaceuticals: Patent expiry, generic penetration, and industry Structure. Eur J Health Econ. 2004;5:175–182.PubMedCrossRefGoogle Scholar
  44. Mestre-Ferrándiz J. The impact of generic goods in the pharmaceutical industry. Health Economics. 1999;8:599–612.CrossRefGoogle Scholar
  45. Moreno I, Puig J, Borrell JR. Generic Entry into the Regulated Spanish Pharmaceutical Market. Rev Industrial Organization. 2009;34(4):373–388.CrossRefGoogle Scholar
  46. Mossialos E, Mrazek M. The Regulation of Pharmacies in Six Countries. Report prepared for the Office of Fair Trading London; 2003.Google Scholar
  47. Motta M. Competition Policy. Theory and Practice. Cambridge University Press; 2004.Google Scholar
  48. Nuscheller R. Physician reimbursement, time, consistency, and the quality of care. J Institutional Theoretical Econ. 2003;159:302–322.CrossRefGoogle Scholar
  49. ÖBIG. Surveying, Assessing and Analyzing the Pharmaceutical Sector in the 25 EU Member States. Report Commissioned by the DG Competition — European Commission. Brussels: Office for Official Publications of the European Communities; 2006.Google Scholar
  50. Puig-Junoy J. Incentives and pharmaceutical reimbursement reforms in Spain. Health Policy. 2004;67:149–145.PubMedCrossRefGoogle Scholar
  51. Puig-Junoy J. Los medicamentos genéricos pagan el precio de ser referencia. Rev Admin Sanit. 2004;2: 35–59.Google Scholar
  52. Puig-Junoy J. The impact of generic reference pricing interventions in the statin market. Health Policy. 2007;84:14–29.PubMedCrossRefGoogle Scholar
  53. Regan TL. Generic entry, price competition, and market segmentation in the prescription drug market. Int J Industrial Organization. 2007.Google Scholar
  54. Reiffen D, Ward ME. Generic drug industry dynamics. Review of Economics and Statistics. 2005;87:37–49.CrossRefGoogle Scholar
  55. Reiffen D, Ward ME. Branded generics’ as a strategy to limit cannibalization of pharmaceutical markets. Managerial and Decision Economics. 2007;28:251–265.CrossRefGoogle Scholar
  56. Rey P. The impact of parallel imports on prescription medicines. Mimeo. 2003.Google Scholar
  57. Rudholm N. Entry and the number of firms in the Swedish pharmaceuticals market. Rev Industrial Organization. 2001;19:351–364.CrossRefGoogle Scholar
  58. Rudholm N. Competition and substitutability in the Swedish pharmaceuticals market. Applied Econ. 2003;35:1609–1617.CrossRefGoogle Scholar
  59. Saha A, Grabowski H, Birnbaum H, Greenberg P. Generic competition in the US pharmaceutical industry. Int J Econ Business. 2006;13:15–38.CrossRefGoogle Scholar
  60. Sauri L. Price Bargaining, Parallel Trade and Incentives to Innovate. European University Institute, Mimeo; 2007.Google Scholar
  61. Scott Morton F. Entry decisions in the generic pharmaceutical industry. RAND J Econ. 1999;30:421–440.PubMedCrossRefGoogle Scholar
  62. Scott Morton F. Barriers to entry, brand advertising, and generic entry in the U.S. pharmaceutical industry. Int J Industrial Organization. 2000;18:1085–1104.CrossRefGoogle Scholar
  63. Segura P. The peculiar patent and generic situation in Spain. Scrip Magazine. 1997;58:23–25.Google Scholar
  64. Schaumans C, Verboven F. Entry and regulation. Evidence from health care professions. RAND J Econ. 2008;22:490–504.Google Scholar
  65. Szymanski S, Valletti TM. Parallel trade, price discrimination, investment and price caps. Economic Policy. 2005;20:705–749.CrossRefGoogle Scholar
  66. Valletti TM. Differential pricing, parallel trade, and the incentive to invest. J Int Econ. 2006;70(1):314–324.CrossRefGoogle Scholar
  67. Waterson M. Retail Pharmacy in Melbourne: Actual and Optimal Densities. J Industrial Economics. 1993;41:403–419.CrossRefGoogle Scholar

Copyright information

© Springer Healthcare Ibérica SL. 2011

Authors and Affiliations

  • Joan-Ramón Borrell

There are no affiliations available

Personalised recommendations